INFLAMMATORY MARKERS AND DISEASE SEVERITY IN NEWBORNS WITH PROLONGED HYPERBILIRUBINEMIA
Keywords:
newborn, hyperbilirubinemia, C-reactive protein, procalcitoninAbstract
Prolonged neonatal hyperbilirubinemia is a disease based on an increase in bilirubin, which is clinically manifested by hyperbilirubinemia for more than 14 days. Given the neurotoxicity of bilirubin on the body of a newborn, a study was also made of markers of inflammation to determine the severity of the disease. Markers of inflammation are known to be used for the differential diagnosis of viral or bacterial etiology of the inflammatory process. To study, we carried out a leukocyte count, a biochemical analysis of blood serum for bilirubin and fractions, as well as inflammation markers C-reactive protein and procalcitonin. This article discusses the difference in the reaction of inflammatory markers depending on the level of bilirubin and the use of pathogenetically scientifically based initial antibiotic therapy in the absence of bacteriolytic confirmation of infection. The difference in the reaction of inflammation markers depending on the perinatal background allows using it for pathogenetically scientifically substantiated starting antibiotic therapy. Distinction of the reaction of markers of inflammation depending on against a background of prenatal infection possible to use for pathogenetic scientifically grounded launching antibiotic therapy lacking bacteriolytic confirmation of infection.
References
Амзаракова Т.Ф. Выявление факторов риска затяжного течения неонатальных желтух / Т.Ф. Амзаракова, А. К. Душина // В мире научных открытий.- 2010.- № 4 (10).- Ч. 9.- С. 95-98.
Белобородова Н.В., Попов Д.А. Тест на прокальцитонин: алгоритмы применения и новые возможности// Пособие для врачей — 2008 С.43-48.
Володин H.H., Дегтярева A.B., Дегтярев Д.Н. Основные причины желтух новорожденных детей и принципы дифференциальной диагностики// Рос.вестник перинатологии и педиатрии.— 2004.— № 5.—С. 18 — 32.
Волынец Г.В., Потапов А.С., Полякова С.И., Александров А.Е., Сенякович В.М., Сурков А.Н., Четкина Т.С., Евлюхина Н.Н., Скворцова Т.А. Определение степени нарушения функции печени у детей. Вопросы современной педиатрии. 2013;12(4):47-51. https://doi.org/10.15690/vsp.v12i4.730
Agata I.D.D', Balistreri W. F. Evaluation of liver diseases in the pediatric patient. Pediatr. Rev. 1999; 20 (11): 376–389.
American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation [published correction appears in Pediatrics. 2004;114(4):1138]. Pediatrics. 2004;114(1):297–316
McDiarmid S. V., Anand R., Lindblad A. S. Development of a pediatric end-stage liver disease score to predict poor outcome in children awaiting liver transplantation. Transplantation. 2002; 74 (2): 173–181.
Stocker M, van Herk W, El Helou S, Dutta S, Fontana MS, Schuerman F, et al. Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns). Lancet. 2017;390:871–81Yan S.T, Sun L.C, Jia H.B, Gao W, Yang J.P, Zhang G.Q.
Procalcitonin levels in bloodstream infections caused by different sources and species of bacteria. Am J Emerg Med. 2017;35:579–83.
Whicher J, Bienvenu J, Monneret G (2001) Procalcitonin as an acute phase marker. Ann Clin Biochem 38:483–493.
Zea-Vera A, Ochoa TJ. Challenges in the diagnosis and management of neonatal sepsis. J Trop Pediatr. 2015;61:1–13.
